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ABSTRACT
Background/Aim: Rome III criteria has modified the description of functional dyspepsia (FD) and divided
this into subgroups. However, the discriminative value of Rome III questionnaire-based diagnosis of FD
is yet to be determined. Objectives: To evaluate the Rome III questionnaire for the diagnosis of FD and
whether it can discriminate between postprandial distress syndrome (PDS) and epigastric pain syndrome
(EPS) in patients with dyspeptic symptoms. Patients and Methods: Consecutive patients, who were not
on proton pump inhibitors (PPI), were asked to participate. Patients who have previously established acid
peptic disease or predominantly reflux symptoms or having alarm symptoms such as weight loss and
hematemesis were excluded. Rome III questionnaire for FD was used to identify the patients as having FD
and divide into its subgroups; PDS or EPS. Gastro-duodenal biopsies, liver function tests and ultrasound
were done to establish the diagnosis of FD. Results: Out of 272 patients with upper gastrointestinal (GI)
symptoms without alarm features, who were enrolled in the study, a total of 191 (70%) fulfilled the criteria
of FD based upon Rome III questionnaire. EPS subgroup was found in 109 (57%), PDS in 17 (9%) patients,
overlap between EPS and PDS was present in 56 (29%) patients. Nine (5%) patients remained indeterminate.
Diagnosis of FD was established in 136/191 (71%) patients only. Gastritis was present in 116 patients (85%),
Duodenitis in 44 (32%) and Helicobacter pylori infection in 70 (51%) patients. Among 55 patients (29%) who
had organic diseases, EPS was seen in 35 (64%), PDS in 5 (9%) and overlap in 15 (27%) patients. Underlying
organic causes were gastric or duodenal ulcers in 14 patients, Barrett esophagus in five, chronic liver disease
in seven, gall stones in five, Giardiasis and celiac disease in three each. Gastric carcinoma, Crohns disease
and gastric polyps were seen in one patient each. Conclusion: This study indicates that 30% of patients
who fulfilled the Rome III criteria for FD actually had organic disease. Almost one-third of patients with
functioanl dyspepsia did not qualify for one of the two subgroups of FD of Rome III. There is also a need
to further define the Rome III-based subgroups of FD for research purpose.
Key Words: Functional dyspepsia, Rome III criteria, epigastric pain syndrome, postprandial distress
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Dyspepsia is a condition of great clinical significance as
a large number of population all over the world, present
with dyspeptic symptoms, visit gastroenterology clinic. The
prevalence of upper gastrointestinal (GI) symptoms is up
to 40% in patients from the Western countries who visit GI
clinics. Majority of them yield no substantial findings during
endoscopy which could possibly explain their symptoms and
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therefore diagnosed as having functional dyspepsia (FD).[1,2]
Patients with dyspepsia typically present with varied and
vague symptoms, and find it difficult to discern between the
subjective feeling of pain and discomfort.[3] Over the years
Rome criteria have been developed to classify dyspepsia
symptoms in certain group for better understanding,
elaborative and much clearer picture.
Rome I committee described FD as chronic or recurrent
pain/discomfort occurring in the upper abdominal region
and divided it into three subgroups (i) ulcer like FD (ii)
dysmotility like FD and (iii) unspecified FD.[4] The Rome
II modified Rome I by sorting subtypes on the basis of
predominant symptoms present in each of the subtype.[5]
The Rome III committee has subclassified FD into two
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main categories namely epigastric pain syndrome (EPS)
and postprandial distress syndrome (PDS). Under this
criterion the GI symptoms are considered to be originating
from the gastro-duodenal region, the pain is centered in
the epigastrium, sharp or burning in quality, the pain is
intermittent, not generalized or localized to other abdominal
or chest regions and not relieved by passage of stool or flatus.
The term FD also encompasses early satiety and bothersome
postprandial fullness which is disproportional to the size of
the meal occurring several times per week.[6]
To classify the patient as having either EPS or PDS, any
organic cause has to be excluded which could likely explain
the symptoms; therefore, upper GI endoscopies, ultrasound
and blood tests are done as this is a diagnosis of exclusion.
The symptoms should be present for the preceding 3 months
while the onset should be 6 months before the diagnosis.
The aim of this study was to evaluate the Rome III
questionnaire for the diagnosis of FD and its usefulness
to discriminate between PDS and EPS in patients with
dyspeptic symptoms.

PATIENTS AND METHODS
Setting

Consecutive new patients who presented in the endoscopy
suite of the Aga Khan University Hospital with dyspeptic
symptoms were recruited; the patients were referred from
the consultant clinic for upper GI endoscopy where history
taking and clinical examinations were done. In addition, the
patients also had complete blood count, urea, creatinine,
electrolytes and liver function tests and ultrasound of upper
abdomen. Patients who had established acid peptic disease by
previous endoscopic examination or those with predominant
heartburn, regurgitation symptoms or a weight loss of more
than 5 kg in the last 6 months were not considered for
possible inclusion in the study.

Inclusion/exclusion criteria

Inclusion criteria for the study was the presence of dyspeptic
symptoms for at least 3 months with the onset being at least 6
months before clinical visit, and absence of exclusion criteria
included the presence of symptoms for a time period shorter
then otherwise specified by the Rome III criteria, history of
abdominal surgeries or finding of any organic cause during
endoscopies such as gastric atrophy, erosive esophagitis,
peptic ulcers and cancers. Patients using NSAIDS and
long-term proton pump inhibitor (PPIs) therapy were also
excluded. Patients with organic, systemic or metabolic
diseases including diabetes which would otherwise explain
these symptoms were also excluded. Multiple biopsies were
taken during endoscopies for histological review and for
absence/presence of Helicobacter pylori.
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Rome III FD questionnaire
Each patient was subjected to the Rome III questionnaire
and the details noted by the doctor who marked the
questionnaire. He was also supposed to explain the question
and queries regarding the meaning of medical terms and
elaboration of symptom when asked by the patients. The
physician who filled the forms was blinded for the results of
endoscopy and other tests. The main reason for this indirect
approach was the lack of English language proficiency in
the population. Interviews were done before the endoscopic
examination by an experienced research officer who is wellversed with the dyspepsia questionnaire.
Endoscopies were performed by two experienced endoscopist
(W.J. and S.A.) who had the experience of doing this
procedure for more than 20 years. All patients underwent
endoscopy and duodenal and gastric biopsies were taken in
all patients. In suspected cases esophageal biopsies were also
taken for excluding Barrett’s esophagus.

Statistical analysis
All analyses were carried out by using the Statistical Package
for Social Sciences (release 13, standard version, SPSS;
Chicago, IL, 2004).

Ethical approval
Informed consent was taken from each patient. The research
protocol was duly approved by the ethics committee of the
University Hospital.

RESULTS
During the study period, 367 patients underwent endoscopic
examination for upper GI symptoms of which 95 were
excluded on the basis of exclusion criteria. A total of 272
consecutive patients, 164 (60%) males and 108 (40%)
females with a mean age of 40± 14.5, were subjected to FD
questionnaire.

Diagnostic yield of Rome III criteria
Out of 272 patients, 191 (70%) fulfilled the Rome III criteria
of FD before confirmation by endoscopy and laboratory
investigation. PDS variant was found in 17 (9%) patients
which was the least dominant of the subtypes of FD. EPS
was found in 109 (57%) patients and overlap between EPS
and PDS was present in 56 (29%) patients. This overlap
occurred because patients fulfilled the symptoms of both
these subtypes, and neither one of them was more dominant.
Nine (5%) patients did not fit the Rome III criteria of either
category.
Diagnosis of FD was established in 136 (71%) patients
after excluding all organic, metabolic and systemic diseases.
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Organic diseases were mainly found in the EPS subgroup
with 35 (64%) patients who fulfill the Rome III questionnaire
criteria for FD before the investigations to rule out organic
diseases, followed by the overlap group 15 (27%) patients
and PDS was present in 5 (9%) patients [Figure 1].

Prevalence of H. pylori in FD patients
H. pylori infection was found in 70 (51%) patients diagnosed
with FD on gastric biopsies. Among subgroups of FD,
H. pylori was seen in 34 (48.5%) patients of EPS, 5 (7%)
patients of PDS group, and 29 (41%) patients of the overlap
group and in two patients who did not fall into either category.

Endoscopic findings
Endoscopy was normal in 136 patients, as they had no
macroscopic abnormality on endoscopy which might explain
their symptoms. Histopathological findings showed gastritis
in 116 (85%) patients and non-specific duodenitis in 44(32%).

Underlying organic causes among patients who
fulfill Rome III questionnaire criteria for FD
Among patients who fulfilled the Rome III criteria for FD
before subjecting to investigation, 55 (29%) patients had
organic diseases. Among these, gastric or duodenal ulcers
were seen in 14 (25.5%), chronic liver disease or hepatitis
in seven (12.8%), gall stones and Barrett’s esophagus in five
(9%) patients each, large hiatal hernia in another five (9%),
Giardiasis and celiac disease was found in three (5.5%)
patients each. Similarly gastric cancer, Crohn’s disease,
gastric outlet obstruction and gastric polyps were the
underlying diseases presented with dyspeptic symptoms in
one patient each [Figure 1].

DISCUSSION
FD is a heterogeneous disorder with diverse symptoms. Due
to this reason the Rome committee has recommended using

Figure 1: Flow chart showing the distribution of uninvestigated dyspepsia after application of Rome III questionnaire
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the term “dyspepsia symptom complex” rather than “FD”
for research.[7] Rome III has tried to group several dyspeptic
and dysmotility symptoms into two major groups i.e., EPS
and PDS. The time interval was also made less limiting for
symptoms.[6] The purpose of this subgroup formation was
to categorize the patient symptoms complex more precisely
and to facilitate the uniformity in defining the patients of
FD for research.
Rome III classification is beneficial for researchers as it
allows them to easily include and exclude patients using
this criterion. However, not every patient fits perfectly into
each category and therefore, results may not accurately
correspond to the patient pool presenting in the clinics.[8]
The present study is the direct evaluation of discriminative
value of Rome III questionnaire for FD in clinical setting.
Our data suggests that Rome III questionnaire for FD was
able to correctly place patients with dyspeptic symptoms into
the FD category two out of three times in a clinical setting
when this criteria was applied to patients with uninvestigated
dyspepsia. In remaining one-third patients, though the Rome
III questionnaire fulfilled the criteria of FD, these patients
had an organic cause for their dyspeptic symptoms. Moreover,
a large number of patients cannot be categorized into either
EPS or PDS subgroup and were left behind uncategorized.
Documented literature has also provided evidence of
significant overlap between presenting symptoms of FD. In
fact a study has shown that a considerable portion of patients
are not classifiable at all.[8]
In a previously published study it was demonstrated that
patients fulfilling criteria for both subgroups of FD had
symptoms that were psychopathologically more severe than
those of patients without overlapping.[9] Ideally, detection
of a specific disease marker may help clinicians make an
accurate diagnosis of conditions like EPS and PDS. This
would help us recognize them as separate disease entities
which, currently, can only be diagnosed after ruling out
everything else.[4]
Although the new criterion does allow us to categorize
patients with a greater ease yet its implication in the
management of patients are not very clear. The present
study did not evaluate the clinical usefulness of Rome III
criteria in the management of FD. However, previous studies
have shown that EPS may be alleviated by using PPIs,[10,11]
similarly symptoms of early satiety related to PDS improve
using prokinetic drugs.[12,13] However, there is no study in the
literature that have tested the effect of PPI or prokinetics in
Rome III-based subgroups of patients with FD. There is need
to explore the effects of specific treatment on FD subgroups
on the basis of Rome III criteria. So far in research settings
treatment of a syndrome based solely on symptoms has not
yet provided satisfactory results.[12-14]
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As FD remains a diagnosis of exclusion, there is more that
needs to be done to precisely diagnose it on the basis of a
defined criterion before using it for the evaluation of specific
treatment outcomes and also in research. Although we had
excluded patients with typical heartburn and regurgitation,
still one would expect some patients to have esophagitis in
the present series; however, it was surprising to note that
none of the patients had erosive esophagitis on endoscopic
examination. However, large hiatus hernia and Barrett’s
esophagus were found in five patients each. A biopsy from
distal esophagus could have further elaborated the frequency
of GERD in this series of patients. Moreover, the proportion
of PDS was somewhat lower than the published series of
patients with FD. This could be related to the fact that it
is a tertiary care setting study where the patients who have
more symptoms are likely to come more than the patients
with PDS. This study is conducted in a high prevalent area
of H. pylori infection and chances for EPS are likely to be
more. Therefore, it should be noted that the present study is
a hospital-based study and the generalizability of this study
is compromised.
In conclusion this study indicates that large number of
patients did not qualify in distinct Rome III-based subgroups
of FD resulting in overlap of symptoms. The Rome III
criterion has neither defined any category for overlap of
symptoms of EPS and PDS, nor the group of patients who
do not fit in to either of the subtypes, and are left without a
subgroup categorization. However, this is a hospital-based
study and may not reflect the true picture of patients with
FD in the primary care setting to whom the patients with
FD belong. We suggest that there is a need to redefine
Rome III subgroups for FD. The addition of a third mixed
symptom group in the Rome III classification of FD and a
possible fourth group of FD patients with indeterminate
symptoms, should be considered. This will probably be more
useful for assessment of outcome following interventional
or exploratory research in FD patients.
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